The ProtecT trial (NCT02044172) was a study conducted between 1999 and 2009 that compared active monitoring, radical prostatectomy and radiotherapy…
Browsing: Acute Lymphoblastic Leukemia
An interesting update on the ProtecT trial (NCT02044172) was given by Freddie Hamdy, MBChB, LRCSPEd, LRCSEd, LRCPSGlasg, FRCSEd, MD, FRCSEd(Urol),…
Patient reported outcomes (PROs) are reports that can provide insightful information from patients, including how they feel about their condition…
Active monitoring, radical prostatectomy or radiotherapy? For men with clinically localized prostate cancer, which intervention has a disease-specific mortality advantage?…
The nurses role in talking about trials was an interesting session run by the UK Oncology Nursing Society (UKONS) symposium…
The National Cancer Research Institute (NCRI) invited the UK Oncology Nursing Society (UKONS) to host a session at the 2017…
Discussing clinical trials with young cancer patients can be tricky; are there certain strategies that can be implemented to help…
It has been found that the Clinical Nurse Specialist has a central role working alongside research nurses and doctors to…
There was exciting news at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, with…
To date, stem cell transplantation has been the best curative treatment method for acute leukemia, for which T-cells are the…
Acute leukemias can exhibit resistance to T-cell engaging antibodies through immune evasion, via both innate and adaptive mechanisms. In this…
T-cell engaging antibodies are more straightforward to deisgn and use in acute lymphoblastic leukemia (ALL) compared with acute myeloid leukemia…
Dr. Thomas George, Medical Director of GI Oncology Program at the University of Florida and a NSABP Principal Investigator discusses…
What were the objectives of the Hokusai venous thromboembolism (VTE)-Cancer Study? In this interview, Harry Buller, MD, PhD, of the…
Venous thromboembolism (VTE) remains a major risk for patients with cancer. The current standard of care for VTE includes subcutaneously…
Our knowledge of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is advancing, as highlighted by an excellent talk on the…
Dr. Karen Reckamp, MD, MS, Co-Director of the Lung Cancer and Thoracic Oncology Program, Medical Director – Clinical Research Operations,…
We are continually learning new facts about the molecular basis of acute lymphoblastic leukemia (ALL) and how it is evolving.…
CAR T-cells for acute lymphoblastic leukemia (ALL) treatment are promising, with a number of different agents in development. Here, Bijal…
It is now widely agreed that minimal residual disease (MRD) is a clinically relevant measure, so how can we now…
Certain molecular lesions are inherently targetable in acute lymphoblastic leukemia (ALL); patients with these changes should be given access to…
Now that our techniques to measure minimal residual disease (MRD) are highlighly sensitive, the utility of MRD to guide and…
Marwan Fakih, MD, explains Identify Who Can Take Immunotherapy in the First-Line The durability of responses would be much better…
Marwan Fakih, MD, shares Presented Data has Affected Day-to-Day Practice Has already been affecting MSI-High patients at the 2018 Oncology…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, shares Comparative Studies in the Neoadjuvant setting All…
Marwan Fakih, MD, explains Disappointing Data for Patients without MSI Great responses to checkpoint inhibitors at the 2018 Oncology Summit…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Trials Evaluating Immunotherapies for Breast Cancer Either…
Marwan Fakih, MD, explains Lack of Randomized Data to Compare Drugs Nivolumab + Ipilimumab showed high response rate Randomized Data…
ara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, explains Not Using Anthracycline-based Therapies Patients accumulate loss…
Marwan Fakih, MD, explains Microsatellite Instability in Colorectal Cancer PD-1 Inhibitors have a significant response rate at the 2018 Oncology…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Immune Therapy Toxicities Related to Breast Cancer…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director shares, TAPUR Study – FDA approved therapies Targeted therapies such as BRAF, CDK2NA,…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, shares Immunotherapy Not Recommended Outside Trials Pembrolizumab for…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director explains, Metastases Treated with Anti-CTLA-4 & Anti-PD-1 Shows immunotherapies to affect brain metastases…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Studies in Neoadjuvant, Curative, & Metastatic Settings…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director explains, Creating Roadmap for Therapies for Solid Tumors Encouraging data shows multiple options…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Immune-Targeted Therapy in Breast Cancer Immune System…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director explains, 238 Trial – Nivolumab as Standard for Melanoma Therapeutics Available for Relapsed…
Acute myeloid leukemia (AML) is experiencing a therapy boom, with increasing numbers of novel treatments being approved and more in…
Elderly patients with secondary acute myeloid leukemia (AML) typically had poor outcomes following standard chemotherapy treatment. However, this changed in…
CPX-351, a combination of cytarabine (ara-C) and daunorubicin within a liposomal delivery system, was approved in August 2017 for two…
The liposomal delivery of chemotherapy is a promising therapeutic area, which was highlighted by the approval of CPX-351 for two…
Hear about exciting advancements in acute lymphocytic leukemia (ALL) with Prof. David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals…
In this exciting interview, Irene Higginson, OBE, BMBS, PhD, FMedSci, FRCP, of Kings College London, London, UK, introduces the palliative…
Nelarabine has shown to be effective in treating relapsed/refractory T-cell acute lymphocytic leukemia (T-ALL) in children and adults; however, there…
Can patients with B-cell acute lymphocytic leukemia (ALL) benefit more from using rituximab as part of their treatment compared to…
In recent years, there has been a lot of debate surrounding how palliative care should be integrated into the cancer…
Palliative care can offer patients with progressive cancer a better quality of life, but how can this type of care…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares When Will Tumor Mutational Burden be a Standard Trials analyzing…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares Stage III Lung Cancer Receptible vs. Unreceptible at the 2018…